Alfresa reported double-digit operating profit growth in Q1FY25. However, the company sees revenue growth but anticipates lower operating and net profits for FY25 due to higher SG&A expenses.
What is covered in the Full Insight:
Introduction
Q1FY25 Financial Performance
Pharmaceutical Wholesaling Business
Future Outlook and Guidance
Conclusion
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.